Adding 11,000 sq.-ft. of production space segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.
Catalent will provide vial filling, packaging capacity and additional staffing for 24x7 manufacturing ops to support production of an initial 100 million doses.
Adds capabilities and technologies for the development and manufacture of autologous and allogeneic cell therapies, as well as related analytical services
Mike Grippo will serve as senior vice president, Strategy and Corporate Development, and Julien Meissonnier as vice president and chief scientific officer